Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
406 - In an unbranded context, is it possible to use a guideline treatment algorithm that recommends drugs that are off label for the condition it pertains?
-
No. The editorial APS provisions of the PAAB code requires that “information on a specific drug is consistent with the current Product Monograph”. Editorial advertising is not the forum for off-label advertising of the sponsor’s product. Note also that the drug class in which the sponsor has a vested interest may not be promoted off-label (e.g. promoted in a manner which is inconsistent with the monographs of all products in that class).
